Futuristic avenues of metabolic engineering techniques in bioremediation

Sharma, Babita; Shukla, Pratyoosh

doi:10.1002/bab.2080

Cited by 32 publications

(11 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…APOA5, PON1, PON3 and CD14 were increased in stage II, an interesting finding, since stage II is at the borderline between a tumor in situ (stage 0-I) and distant metastasis (stage III-IV). APOA5, expressed by platelet-derived EV (ExoCarta) and podocyte-specific CR1-immunocaptured urine exosomes, modulates intra/extracellular triacylglycerol metabolism [85,86], and this may relate to the differences measured in FA composition. PON1 is implicated in eliminating carcinogenic lipid-soluble radicals.…”

Section: Discussionmentioning

confidence: 99%

The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients

Paolino

Huber

Camerini³

et al. 2021

Cancers

View full text Add to dashboard Cite

The early detection of cutaneous melanoma, a potentially lethal cancer with rising incidence, is fundamental to increasing survival and therapeutic adjustment. In stages II–IV especially, additional indications for adjuvant therapy purposes after resection and for treatment of metastatic patients are urgently needed. We investigated whether the fatty acid (FA) and protein compositions of small extracellular vesicles (sEV) derived from the plasma of stage 0–I, II and III–IV melanoma patients (n = 38) could reflect disease stage. The subpopulation of sEV expressing CD81 EV marker (CD81sEV) was captured by an ad hoc immune affinity technique from plasma depleted of large EV. Biological macromolecules were investigated by gas chromatography and mass spectrometry in CD81sEV. A higher content of FA was detectable in patients with respect to healthy donors (HD). Moreover, a higher C18:0/C18:1 ratio, as a marker of cell membrane fluidity, distinguished early (stage 0–I) from late (III–IV) stages’ CD81sEV. Proteomics detected increases in CD14, PON1, PON3 and APOA5 exclusively in stage II CD81sEV, and RAP1B was decreased in stage III–IV CD81sEV, in comparison to HD. Our results suggest that stage dependent alterations in CD81sEV’ FA and protein composition may occur early after disease onset, strengthening the potential of circulating sEV as a source of discriminatory information for early diagnosis, prediction of metastatic behavior and following up of melanoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients

Paolino

Huber

Camerini³

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…APOA5, PON1, PON3, CD14 were increased in stage II, an interesting finding since stage II is at borderline between tumor in situ (stage 0-I) and distant metastasis (stage III-IV). APOA5, expressed by platelet-derived EV (ExoCarta) and podocyte-specific CR1-immunocaptured urine exosomes, modulates intra/extracellular triacylglycerol metabolism [53,54] and this may relate to the differences measured in FA composition. PON1, is implicated in eliminating carcinogenic lipid-soluble radicals.…”

Section: Discussionmentioning

confidence: 99%

Fatty acid and proteomic signatures of circulating CD81 positive small extracellular vesicles define the disease stage in melanoma patients

Paolino¹,

Huber²,

Camerini³

et al. 2021

Preprint

View full text Add to dashboard Cite

The early detection of cutaneous melanoma, a potentially lethal cancer with rising incidence, is key to increase survival and therapeutic adjustment. Especially in stages II-IV biomarkers are urgently needed for adjuvant therapy purposes after resection and for treatment of metastatic patients. We here investigated if fatty acid (FA) and protein composition of small extracellular vesicles (sEV) deriving from plasma of 0-I, II, and III-IV stage melanoma patients (n=38) could reflect disease stage and thus function as biomarker. The subpopulation of sEV expressing CD81 (CD81sEV) was isolated by an ad hoc immune affinity technique from microvesicle-depleted plasma. Biological macromolecules were investigated by gas chromatography and mass spectrometry in CD81sEV. A higher content of FA and a decrease in Saturation Index (C18:0/C18:1), already detectable in early stages, distinguished patients’ from healthy donor CD81sEV. Proteomics (identifier PXD024434) detected an exclusive and significant increase of CD14, PON1, PON3 and APOA5 in stage II and a significant decrease of Rap1b in stage III-IV CD81sEV. The FA and proteomic stage dependent CD81sEV signature strengthens the potential of circulating sEV studies in providing discriminatory information for early diagnosis, prediction of metastatic behavior and follow up of melanoma patients.

show abstract

“…Model systems for studying functional and structural characteristics can be found in these communities. Synthetic communities were formed by the co-culturing of two distinct microorganisms under precisely defined conditions, which were based on their interactions and functions [171]. The community's dynamics and structure are determined by these variables; it is based on the discovery of bacterial processes and behaviors.…”

Section: Designing the Synthetic Microbial Communitiesmentioning

confidence: 99%

Recent Strategies for Bioremediation of Emerging Pollutants: A Review for a Green and Sustainable Environment

Bala

Garg

Thirumalesh

et al. 2022

Toxics

293

View full text Add to dashboard Cite

Environmental pollution brought on by xenobiotics and other related recalcitrant compounds have recently been identified as a major risk to both human health and the natural environment. Due to their toxicity and non-biodegradability, a wide range of pollutants, such as heavy metals, polychlorinated biphenyls, plastics, and various agrochemicals are present in the environment. Bioremediation is an effective cleaning technique for removing toxic waste from polluted environments that is gaining popularity. Various microorganisms, including aerobes and anaerobes, are used in bioremediation to treat contaminated sites. Microorganisms play a major role in bioremediation, given that it is a process in which hazardous wastes and pollutants are eliminated, degraded, detoxified, and immobilized. Pollutants are degraded and converted to less toxic forms, which is a primary goal of bioremediation. Ex situ or in situ bioremediation can be used, depending on a variety of factors, such as cost, pollutant types, and concentration. As a result, a suitable bioremediation method has been chosen. This review focuses on the most recent developments in bioremediation techniques, how microorganisms break down different pollutants, and what the future holds for bioremediation in order to reduce the amount of pollution in the world.

show abstract

Futuristic avenues of metabolic engineering techniques in bioremediation

Cited by 32 publications

References 74 publications

The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients

The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients

Fatty acid and proteomic signatures of circulating CD81 positive small extracellular vesicles define the disease stage in melanoma patients

Recent Strategies for Bioremediation of Emerging Pollutants: A Review for a Green and Sustainable Environment

Contact Info

Product

Resources

About